1 / 6

Head and Neck Cancer Drugs Market impact positively in Medical sectors with the help of new Strategy

The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

newmarketindustry
Télécharger la présentation

Head and Neck Cancer Drugs Market impact positively in Medical sectors with the help of new Strategy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Increase in incidence of head & neck cancer play a major role in the growth of the head & neck cancer drugs market. Furthermore, increase in use of combination therapy and growth in demand for target immune therapy in the developing countries are expected to boost the market growth in the coming years. Head & Neck Cancer Drugs Marketwas valued at $1,295 million in 2017, and is expected to reach $2,281 million by 2025, growing at a CAGR of 7.3% from 2018 to 2025. Get Sample Report

  2. Head & neck cancer drugs include chemotherapy and targeted & immune therapeutic drugs, which are used alone or in combination for treatment of throat, larynx, nose, sinuses, lips, salivary glands, and mouth cancers. It is estimated that head & neck cancer drugs market is expected to exhibit significant market growth over the forecast period due to growth in number of target population, rise in demand for combination therapy, advancement in screening & diagnosis procedures, and expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, and Bevacizumab.

  3. Based on drug class, the global head & neck cancer drugs market is categorized as chemotherapy agents, immunotherapy, and targeted therapy. Chemotherapy was the major revenue contributing segment in 2017, due to increase in adoption of chemotherapeutics for treatment of head & neck cancer along with radiation therapy and rise in demand for combination therapy. However, the market for immune therapeutic drugs is projected to exhibit the fastest market growth during the forecast period owing to strong presence of pipeline drugs, rise in usage of Yervoy & Keytruda along with the supportive reimbursement policies for usage of immunotherapy drugs in some countries.

  4. Key Findings of the Head & Neck Cancer Drugs Market: • Based on sales channel, the online stores segment is expected to experience fastest market and is projected to grow at a CAGR of 10.2% during the forecast period 2018-2025. • Depending on drug class, the chemotherapy segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 4.0% from 2018 to 2025. • Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.7% during the forecast period.

  5. The key players profiled in this report include AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.

More Related